Scientists from the Institut Pasteur Paris led by Roland Brosch and Laleh Majlessi (Unit for Integrated Mycobacterial Pathogenomics), working in collaboration with a team from Italy (Department of Biology, University of Pisa), have published the results of their research into the action mechanisms of a promising experimental tuberculosis (TB) vaccine in the journal PLOS Pathogens. BCG, the only currently approved TB vaccine, has been around for almost a century, but it is only partially effective and the protection it offers fades over time. Given the current emergence of adult TB cases in conjunction with the HIV epidemic and the rise in multidrug-resistant TB strains, the development of a new, more effective vaccine is a global health priority. This research was conducted in connection with the TBVAC2020 European consortium.
CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection, PLoS Pathog. July 28, 2016 DOI : 10.1371/journal.ppat.1005770.
Read the full story on Institut Pasteur website.